2,3-Diaryl-2H-1-benzopyran derivatives interfere with classical and non-classical estrogen receptor signaling pathways, inhibit Akt activation and induce apoptosis in human endometrial cancer cells

Molecular and Cellular Endocrinology

Volumn 348, Issue 1, 2012, Pages 198-210

  Fatima, I ^a   Chandra, V ^a   Saxena, R ^a   Manohar, M ^a   Sanghani, Y ^a   Hajela, K ^a   Negi, M P S ^a   Sankhwar, P L ^b   Jain, S K ^c   Dwivedi, A ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c HAMDARD UNIVERSITY   (India)

Author keywords

Apoptosis; Benzopyrans; Endometrial cancer

Indexed keywords

2 (PIPERIDINOETHOXYPHENYL) 3 PHENYL 2H BENZOPYRAN; 2,3 DIARYL 2H 1 BENZOPYRAN DERIVATIVE; BENZOPYRAN DERIVATIVE; CASPASE 3; CASPASE 9; CYCLIN D1; CYCLINE; ESTROGEN RECEPTOR; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CDC2 GENE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYCLINE1 GENE; ENDOMETRIUM CANCER; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; GENE; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BENZOPYRANS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLIN B; CYCLIN D1; CYCLIN E; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOMETRIAL NEOPLASMS; ENZYME ACTIVATION; ESTRADIOL; FEMALE; HUMANS; ONCOGENE PROTEINS; PIPERIDINES; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SIGNAL TRANSDUCTION; TRANSCRIPTIONAL ACTIVATION;

EID: 80755135465     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.08.018     Document Type: Article

References (45)

1. Bjornstrom L., Sjoberg M. Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol. Endocrinol. 2005, 19:833-842.
2. Blesson C.S., Awasthi S., Kharkwal G., Daverey A., Dwivedi A. Modulation of estrogen receptor transactivation and estrogen-induced gene expression by ormeloxifene-a triphenylethylene derivative. Steroids 2006, 71:993-1000.
3. Bouskine A., Nebout M., Mograbi B., Brucker-Davis F., Roger C., Fenichel P. Estrogens promote human testicular germ cell cancer through a membrane-mediated activation of extracellular regulated kinase and protein kinase A. Endocrinology 2008, 149:565-573.
4. Cancer facts and figures. American Cancer Society, 2010.
5. Castoria G., Migliaccio A., Bilancio A., Di Domenico M., de Falco A., Lombardi M., Fiorentino R., Varricchio L., Barone M.V., Auricchio F. PI3-kinase in concert with Src promotes the S-phase entry of oestradiol-stimulated MCF-7 cells. Embo. J. 2001, 20:6050-6059.
6. Couillard S., Labrie C., Belanger A., Candas B., Pouliot F., Labrie F. Effect of dehydroepiandrosterone and the antiestrogen EM-800 on growth of human ZR-75-1 breast cancer xenografts. J. Natl. Cancer. Inst. 1998, 90:772-778.
7. Dai D., Litman E.S., Schonteich E., Leslie K.K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J. Steroid Biochem. Mol. Biol. 2003, 87:123-131.
8. Dan H.C., Sun M., Kaneko S., Feldman R.I., Nicosia S.V., Wang H.G., Tsang B.K., Cheng J.Q. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). J. Biol. Chem. 2004, 279:5405-5412.
9. Dey R., Moraes C.T. Lack of oxidative phosphorylation and low mitochondrial membrane potential decrease susceptibility to apoptosis and do not modulate the protective effect of Bcl-x(L) in osteosarcoma cells. J. Biol. Chem. 2000, 275:7087-7094.
10. Dhar J.D., Setty B.S., Duran S., Kapil R.S. Biological profile of 2-[4-(2-N-piperidinoethoxy) phenyl]-3-phenyl (2H) benzo (b) pyran - a potent antiimplantation agent in rat. Contraception 1991, 44:461-472.
11. Fleming G.F. Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant. J. Clin. Oncol. 2007, 25:2983-2990.
12. Gauthier S., Caron B., Cloutier J., Dory Y.L., Favre A., Larouche D., Mailhot J., Ouellet C., Schwerdtfeger A., Leblanc G., Martel C., Simard J., Merand Y., Belanger A., Labrie C., Labrie F. (S)-(+)-4-[7-(2,2-dimethyl-1-oxopropoxy)-4-methyl-2-[4-[2-(1-piperidinyl)- ethoxy]phenyl]-2H-1-benzopyran-3-yl]-phenyl 2,2-dimethylpropanoate (EM-800): a highly potent, specific, and orally active nonsteroidal antiestrogen. J. Med. Chem. 1997, 40:2117-2122.
13. Genc S., Attar E., Gurdol F., Kendigelen S., Bilir A., Serdaroglu H. The effect of COX-2 inhibitor, nimesulide, on angiogenetic factors in primary endometrial carcinoma cell culture. Clin. Exp. Med. 2007, 7:6-10.
14. Gielen S.C., Santegoets L.A., Kuhne L.C., Van Ijcken W.F., Boers-Sijmons B., Hanifi-Moghaddam P., Helmerhorst T.J., Blok L.J., Burger C.W. Genomic and nongenomic effects of estrogen signaling in human endometrial cells: involvement of the growth factor receptor signaling downstream AKT pathway. Reprod. Sci. 2007, 14:646-654.
15. Guohong Z., Vanessa G., Steven R.K., Guochen Y. Early detection of apoptosis using a fluorescent conjugate of annexin V. Biotechniques 1997, 23:525-532.
16. Hermenegildo C., Cano A. Pure anti-oestrogens. Hum. Reprod. Update 2000, 6:237-243.
17. Holinka C.F., Anzai Y., Hata H., Kimmel N., Kuramoto H., Gurpide E. Proliferation and responsiveness to estrogen of human endometrial cancer cells under serum-free culture conditions. Cancer Res. 1989, 49:3297-3301.
18. Ito, K, Utsunomiyaa, H, Niikuraa, H, Yaegashia, N, Sasanob, H, 2011. Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine therapy for endometrial cancer and ovarian cancer. Mol. Cell. Endocrinol. doi:10.1016/j.mce.2010.11.023.
19. Jakacka M., Ito M., Weiss J., Chien P.Y., Gehm B.D., Jameson J.L. Estrogen receptor binding to DNA is not required for its activity through the nonclassical AP1 pathway. J. Biol. Chem. 2001, 276:13615-13621.
20. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun M.J. Cancer statistics. CA Cancer J. Clin. 2008, 58:71-96.
21. Kapil, R.S., Durani, S., Dhar, J.D., Setty, B.S., 1990. Novel benzopyrans and process for their production. European Patent No. 90308787/2.
22. Katzenellenbogen B.S., Montano M.M., Le Goff P., Schodin D.J., Kraus W.L., Bhardwaj B., Fujimoto N. Antiestrogens: mechanisms and actions in target cells. J. Steroid Biochem. Mol. Biol. 1995, 53:387-393.
23. Kayisli U.A., Guzeloglu-Kayisli O., Arici A. Endocrine-immune interactions in human endometrium. Ann. N. Y. Acad. Sci. 2004, 1034:50-63.
24. Kharkwal G., Fatima I., Kitchlu S., Singh B., Hajela K., Dwivedi A. Anti-implantation effect of 2-[piperidinoethoxyphenyl]-3-[4-hydroxyphenyl]-2H-benzo(b)pyran, a potent antiestrogenic agent in rats. Fertil. Steril. 2011, 95:1322-1327.
25. Markman M. Systemic therapy for gynecologic cancer. Curr. Opin. Oncol. 1992, 4:939-945.
26. McMeekin D.S., Gordon A., Fowler J., Melemed A., Buller R., Burke T., Bloss J., Sabbatini P. A phase II trial of arzoxifene, a selective estrogen response modulator, in patients with recurrent or advanced endometrial cancer. Gynecol. Oncol. 2003, 90:64-69.
27. Neijt J.P. Advances in the chemotherapy of gynecologic cancer. Curr. Opin. Oncol. 1994, 6:531-538.
28. Nicholson K.M., Anderson N.G. The protein kinase B/Akt signalling pathway in human malignancy. Cell Signal. 2002, 14:381-395.
29. Nilsson S., Makela S., Treuter E., Tujague M., Thomsen J., Andersson G., Enmark E., Pettersson K., Warner M., Gustafsson J.A. Mechanisms of estrogen action. Physiol. Rev. 2001, 81:1535-1565.
30. Pugazhenthi S., Nesterova A., Sable C., Heidenreich K.A., Boxer L.M., Heasley L.E., Reusch J.E. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 2000, 275:10761-10766.
31. Safe S., Kim K. Non-classical genomic estrogen receptor (ER)/specificity protein and ER/activating protein-1 signaling pathways. J. Mol. Endocrinol. 2008, 41:263-275.
32. Satyaswaroop P.G., Clarke C.L., Zaino R.J., Mortel R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. Cancer Lett. 1992, 62:107-114.
33. Scheid M.P., Woodgett J.R. PKB/AKT: functional insights from genetic models. Nat. Rev. Mol. Cell. Biol. 2001, 2:760-768.
34. Scott F.L., Denault J.B., Riedl S.J., Shin H., Renatus M., Salvesen G.S. XIAP inhibits caspase-3 and -7 using two binding sites: evolutionarily conserved mechanism of IAPs. Embo. J. 2005, 24:645-655.
35. Sharma A.P., Saeed A., Durani S., Kapil R.S. Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. J. Med. Chem. 1990, 33:3216-3222.
36. Shaulian E., Karin M. AP-1 as a regulator of cell life and death. Nat. Cell. Biol. 2002, 4:E131-E136.
37. Shiozaki E.N., Chai J., Rigotti D.J., Riedl S.J., Li P., Srinivasula S.M., Alnemri E.S., Fairman R., Shi Y. Mechanism of XIAP-mediated inhibition of caspase-9. Mol. Cell. 2003, 11:519-527.
38. Sorosky J.I. Endometrial cancer. Obstet. Gynecol. 2008, 111:436-447.
39. Wan X., Yokoyama Y., Shinohara A., Takahashi Y., Tamaya T. PTEN augments staurosporine-induced apoptosis in PTEN-null Ishikawa cells by downregulating PI3K/Akt signaling pathway. Cell Death Differ. 2002, 9:414-420.
40. Yahata T., Fujita K., Aoki Y., Tanaka K. Long-term conservative therapy for endometrial adenocarcinoma in young women. Hum. Reprod. 2006, 21:1070-1075.
41. Yamaguchi H., Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 2001, 20:7779-7786.
42. Yuan Z.Q., Feldman R.I., Sussman G.E., Coppola D., Nicosia S.V., Cheng J.Q. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. J. Biol. Chem. 2003, 278:23432-23440.
43. Zagouri, F., Bozas, G., Kafantari, E., Tsiatas, M., Nikitas, N., Dimopoulos, M.A., Papadimitriou, C.A., 2010. Endometrial cancer: what is new in adjuvant and molecularly targeted therapy? Obstet. Gynecol. Int. 749579.
44. Zar J.H. Biostatistical analysis 1974, Prentice Hall Inc., Englewood Cliffs, New Jersey.
45. Zhang L., Li X., Zhao L., Zhang L., Zhang G., Wang J., Wei L. Nongenomic effect of estrogen on the MAPK signaling pathway and calcium influx in endometrial carcinoma cells. J. Cell. Biochem. 2009, 106:553-562.